UC Santa Cruz study shows psilocybin reorganizes neural connections

Psilocybin rapidly reorganizes neural connections in the mammalian brain, according to a study published October 15 in Nature Neuroscience by researchers at the University of California, Santa Cruz. The findings show that the psychedelic compound stimulates nerve cells to form new dendritic spines while simultaneously pruning older connections, opening a potential path toward treatments for psychiatric disorders that might not require hallucinogenic side effects.

Federal Restrictions Halted Mid-Century Research Before Recent Scientific Revival

Scientific exploration of psilocybin and related compounds began in the middle of the 20th century as researchers investigated their profound effects on perception and mood. That early momentum halted after the United States passed the Controlled Substances Act in 1970, which placed severe federal restrictions on psychedelic research. In recent decades, renewed scientific interest has focused on the ability of these substances to act as psychoplastogens, compounds capable of triggering rapid neuroplasticity after a single dose.

The U.S. Food and Drug Administration granted Breakthrough Therapy designations to psilocybin and MDMA to accelerate their clinical evaluation for serious mental health conditions. By September 2026, the agency advanced its regulatory framework by organizing a public hearing titled “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs,” where experts examined clinical trial design, provider qualifications, and Risk Evaluation and Mitigation Strategy programs.

Two-Photon Microscopy Reveals Synaptic Maturation

To observe these structural modifications in real time, senior author Yi Zuo and lead author Jacob Baker used two-photon microscopy to track individual neuronal connections in living mice over several weeks. Within 24 hours of psilocybin exposure, the imaging revealed a substantial surge in newly forming dendritic spines, the tiny cellular protrusions that receive chemical messages across synapses.

Rather than remaining unstable or disappearing, a high proportion of these new spines rapidly matured into distinctive mushroom-shaped structures. These mature connections contain dense concentrations of neurotransmitter receptors, allowing them to support persistent communication loops across neural circuits involved in memory and emotional regulation.

Differential Effects on Stressed and Healthy Brains

The structural impact of psilocybin varied depending on whether the test subjects had experienced prior chronic stress. In healthy mice, an initial spike in spine formation was followed by a gradual return to baseline over three weeks as the brain pruned older connections to maintain overall homeostatic balance.

Mice subjected to unpredictable mild stress exhibited a distinctly different cellular response. Chronic stress typically degrades synaptic connections and disrupts neural circuitry, mimicking features of human depression. When stressed mice received psilocybin, the compound not only stimulated vigorous new spine formation but also prevented the accelerated connection loss characteristic of prolonged stress.

Isolating Rewiring From Hallucinogenic Response

To determine whether structural brain changes require altered states of consciousness, the research team manipulated serotonin 2A receptors on Layer 5 pyramidal neurons within the cerebral cortex. Selectively restoring these receptors in Layer 5 neurons allowed psilocybin to promote synapse formation and stability without triggering the head-twitch response commonly used as a behavioral marker of psychedelic activity in rodents.

Conversely, removing serotonin 2A receptors from these specific neurons eliminated psilocybin’s ability to drive structural growth, though the mice still displayed the behavioral head-twitch response. These opposing outcomes demonstrate that structural neuroplasticity and behavioral psychedelic markers operate through distinct cellular pathways.

I consider this work a major advance, particularly in our understanding of how psilocybin reshapes neural circuits and its potential implications for treating mental disorders,

said senior author Yi Zuo, professor of molecular, cell, and developmental biology at UC Santa Cruz.

The identification of these distinct cellular mechanisms provides a foundational framework for developing targeted psychiatric medications. If future drug development can harness psilocybin’s capacity for structural reorganization without engaging the neural pathways responsible for hallucinations, clinicians may eventually gain a precise pharmacological tool for treating treatment-resistant depression, post-traumatic stress disorder, and related conditions.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.